Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award


Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award


May 11, 2023


WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio is pleased to announce that its founder and CEO, Dr. Ryan Saadi, has been named the recipient of the prestigious Boy Scouts of America Distinguished Citizen Award. Dr. Saadi will accept the award at the Boy Scouts of America Patriots’ Path Council’s 5th Project STEM Awards Dinner on Wednesday, June 14th at the Bridgewater Marriott.


The Boy Scouts of America’s (BSA) STEM (Science, Technology, Engineering, and Math) programs give Scouts an opportunity to explore relevant skills and experiences and to be recognized for their achievements. The BSA has partnered with institutions like MITCarnegie-Mellon and ExxonMobil to create merit badges in STEM, robotics, and inventing. Currently the BSA offers over 80 STEM related merit badges. The BSA’s focus on cultivating young minds to excel in STEM fields aligns with Tevogen Bio’s mission to pioneer cutting-edge research and create innovative solutions for some of the world’s most pressing challenges.



“Dr. Saadi’s background as an Eagle Scout has undoubtedly played a significant role in shaping his character and leadership qualities,” said Susan Podlogar, Chief Human Resources Officer at MetLife and member of Tevogen’s Board of Directors. “His commitment to the values in the Scout Oath and Law is evident in his dedication to making a positive impact on society. We take immense pride in having him as Tevogen’s CEO and congratulate him on this well-deserved recognition as a Distinguished Citizen.” Susan will also serve as the Event Chair for the evening’s elegant celebration.



Professor Sten Vermund, MD, PhD, of Yale University, a member of the company’s Corporate Board, shared his thoughts on Dr. Saadi’s achievements, “Dr. Ryan Saadi’s steadfast commitment to health equality and his pursuit of innovative solutions to global medical challenges truly set him apart as a visionary leader in the scientific community. His achievements as both an Eagle Scout and the CEO of Tevogen Bio exemplify the power of dedication and perseverance, making him a deserving recipient of the Boy Scouts of America Distinguished Citizen Award.”


“Dr. Saadi, the founder of Tevogen Bio, has devoted his life’s work to promoting health equality, earning him a nomination for the esteemed 2023 Nobel Peace Prize,” said Victor Sordillo, also a member of Tevogen’s Corporate Board. “His unparalleled dedication to enhancing human health through accessible biotechnology and making a positive impact on society is a testament to his unwavering commitment to improving the lives of people worldwide.”


“We take great pride in our commitment to inspiring and nurturing the next generation of scientists, engineers, and innovators who will make a significant impact on the future of our world,” said Tevogen’s emerging leaders Ashley HutchinsonAlly O’Connor, and Wojtek Stobinski.


For more information on attending and sponsoring the program journal, please contact Jennifer Volz, Senior Development Director, at 973-765-9322, ext. 249, and/or jennifer.volz@scouting.org. To sign up for the event or donate, visit http://www.ppcbsa.org/special-events.




About Tevogen’s Next Generation Precision T Cell Platform


Tevogen’s next generation precision T cell platform is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple, precise candidate targets on viral or malignant cells are selected in advance for T cell sensitization and effector functions with the goal of overcoming the mutational escape capacity of cancer cells and viruses while limiting cross-reactivity.


Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to provide access to the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections. The ability to administer TVGN-489 in the outpatient setting and the ongoing work by Tevogen scientists to use this product in diverse patient populations, highlights Tevogen Bio’s commitment to patient accessibility.




About Tevogen Bio


Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.




Forward Looking Statements


This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.





Tevogen Communications

T: 1 877 TEVOGEN, Ext 701